Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Precipio Inc PRPO

Healthcare
Precipio, Inc. is a healthcare biotechnology company that is focused on cancer diagnostics. It develops and sells diagnostic products, reagents and services that improve the accuracy and efficiency of diagnostics, and lead to fewer misdiagnoses. The Company’s technologies include HemeScreen and IV-Cell. IV-Cell is a cell culture media that addresses the problem of diagnostic mistakes through... see more

Recent & Breaking News (NDAQ:PRPO)

Precipio Continues to Sign New HemeScreen(TM) Customers

GlobeNewswire September 28, 2023

Precipio Reduces Product Revenue Result Needed for Cash Flow Breakeven

GlobeNewswire September 25, 2023

Precipio Takes Final Step Towards Regaining Nasdaq Compliance

GlobeNewswire September 21, 2023

Precipio's Pathology Division Exceeds Breakeven Revenues in August, Four Months Ahead of Plan

GlobeNewswire September 13, 2023

Precipio Announces Q2-2023 Shareholder Update Call

GlobeNewswire August 10, 2023

Precipio Launches Its Much-Anticipated Quantitative BCR-ABL 2.0 Panel

GlobeNewswire August 8, 2023

Precipio's Operational Efficiency Measures Continue To Reduce Cash Burn And Move The Company Towards Breakeven

GlobeNewswire August 3, 2023

Precipio Unaudited Q2-2023 Revenues Show combined increase of 25% over Q1-2023

GlobeNewswire August 1, 2023

Precipio's Omnia(TM) Methodology Enables Diagnosis of MDS With Peripheral Blood Instead of Bone Marrow Biopsy

GlobeNewswire June 14, 2023

Precipio Enters into Collaboration with Prestigious New York-based Institution to Develop Revolutionary Brain Tumor Panel using HemeScreen® Technology

GlobeNewswire June 13, 2023

Precipio, Inc. Announces Pricing of $2 Million Registered Direct Offering and Concurrent Private Placement

GlobeNewswire June 8, 2023

Projected cash burn reduced by $1.5 million annually from Three Operational Efficiency Projects

GlobeNewswire June 7, 2023

Precipio's Lab Detects BCR-ABL1 Oncogene Co-Expression of p190 & p210 Isoforms in a CML Patient By Using HemeScreen® Technology

GlobeNewswire May 22, 2023

Precipio Shares Growth Catalysts For HemeScreen

GlobeNewswire May 17, 2023

Precipio Announces Q1-2023 Shareholder Update Call

GlobeNewswire May 15, 2023

Precipio Adds Substantial Pathology Customer to its Diagnostic Services Division

GlobeNewswire May 4, 2023

Precipio Signs Another HemeScreen(TM) Customer

GlobeNewswire May 4, 2023

Precipio Granted 180-day Extension From NASDAQ To Regain Compliance

GlobeNewswire April 27, 2023

Precipio Unaudited Q1-2023 Product Revenues Exceed The Two Prior Quarters (Q3+Q4 of 2022) Combined

GlobeNewswire April 19, 2023

Precipio Announces 2022 Fourth Quarter and Year-End Shareholder Update Call

GlobeNewswire March 28, 2023